• Epinephrine Options

    Here is a pdf for easy printing... 2017 Epinephrine Options.pdf

  • Food Allergy Awareness Week

    May 14-20 is Food Allergy Awareness Week! 

    PAK is jazzing up your May with THREE incredible meetings plus a DARE to raise awareness... www.pakcharlotte.org/dare 

    Saturday, May 13, 3:00 - 5:00 PM: PAK Baking Class Featuring a Baking Panel: Leigh Ann Worley:  creating Silhouette images, Gabby Starr of Gab’s Goodies: cupcake decorating, Mary Herrington of Mrs. GF: gluten free baking. There will be short demos for each topic and a Q&A at the end. Feel free to take away an arsenal of baking tips and tools. This is for adults only. The ingredients used at this demo can be tweeked to tailor to your own personal allergy set. RSVP to info@pakcharlotte.org This event will be held at St. Matthew Catholic Church in the Parish Center Kitchen 8015 Ballantyne Commons Pkwy 28277
    Thursday, May 18, 7:00 PM: Bridge the Nutrition Gap
    Raquel Durban is a registered dietitian with the Food Allergy Institute of Charlotte. She will lead an educational session of Bridging the Gap to connect diagnosis to management. Management is more than food avoidance, it's focusing on what is available and how it provides fuel to the body while ensuring quality of life. Let us know what topics and information you would like to discuss so Raquel may shape this discussion to be more integrative and informative! RSVP and send questions to: info@pakcharlotte.org  This meeting will be held at St. Matthew Catholic Church in the Parish Center Family Room 8015 Ballantyne Commons Pkwy Clt  28277 
     
    Saturday, May 20, 1:30 PM - 4:00 PM: Bring Your Friends: To Learn About Allergies & Anaphylaxis Guest Speakers: Dr. Maeve O'Connor with AAIR of Charlotte, Dr. Aerick Williams of Allergy Partners of Rowan-Salisbury, Jon Eccleston, MSW from Carolinas Therapy Solutions  
    Who: For PAK Families Ages Kindergarten - High School
    What: INVITE YOUR FRIENDS...Let’s “PAK” the Library! As part of Food Allergy Awareness Week, this will be an opportunity to chat with the Charlotte community allergists and therapist to help our friends gain better understanding of how we manage allergies.
    1:30 - 2:00 PM will be a panel discussion for all
    2:00 - 4:00 PM Round Table discussions Topics will include epinephrine training, what happens during a reaction and the emotional impact it has on our lives broken down into age groups
    Where: Charlotte Mecklenburg South County Public Library 5801 Rea Rd, Charlotte, NC 28277 in their Community Room
    RSVP with ages of attendees to help the guest speakers plan accordingly:info@pakcharlotte.org

    SAVE THE DATE: First Ever PAK 5K at the Yiasou Greek Festival 5K Price goes up on June 22, so secure your space today!
    Saturday, August 26 7:30 AM - 9:00 AM at the Holy Trinity Greek Orthodox Cathedral
    600 East Blvd, Charlotte, North Carolina 28203 We are overjoyed to announce PAK will have a 5K this summer thanks to our Premier Sponsor, Food Allergy Institute of Charlotte! To Register, go tohttps://runsignup.com/Race/NC/Charlotte/YiasouGreekFestival5K  There will be a place to enter our code “PAK” which will give PAK 10$ per adult and 5$ per student! Please share this post on your personal pages and send to all the runners you know! 
  • DARE TO BE...JUST LIKE ME

    DARE TO BE...JUST LIKE ME 
    With Food Allergy Awareness Week approaching, we are enlisting you, our members, to raise awareness like you have never done before! We are thrilled to roll out a new endeavor, Dare to Be...Just like Me. Although we are managing different allergies, as members of Parents of Allergic Kids, we have one thing in common. We wish people truly understood what it is like for our children and our families to manage food allergies. It is not simply removing a food. Food is everywhere. It is all encompassing for celebrations, holidays, school events, each and every day we have to keep vigilant. We want this to be the next online viral sensation to raise awareness about living with food allergies, EoE and other dietary restrictions. Please share this on all of your social media outlets, Facebook, Instagram, Twitter, email, etc. in addition to challenging your own family and friends. This fabulous challenge was brought to us by PAK mom, Kerrie Sperduto  and her sweet daughter Gabriella. To learn how it all began and to get more details and tips to have a successful DARE, check out  www.pakcharlotte.org/dare

  • Epipen Recall in the US

    For our PAK members that have the Epipen brand autoinjector: 
    Please go to the Mylan website to see if the lot numbers on the Epipen devices you have are part of this recall. Be sure to call the schools and other caregivers that may have sets...
    http://www.mylan.com/en/epipenrecall 

    Mylan Provides Update on Meridian Medical Technologies', a Pfizer Company, Expanded Voluntary Worldwide Recall of EpiPen® Auto-Injector

    HERTFORDSHIRE, England and PITTSBURGH, March 31, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that Meridian Medical Technologies, a Pfizer company and Mylan's manufacturing partner for EpiPen® Auto-Injector, has expanded a voluntary recall of select lots of EpiPen (epinephrine injection, USP) and EpiPen Jr® (epinephrine injection, USP) Auto-Injectors to now include additional lots distributed in the U.S. and other markets in consultation with the U.S. Food and Drug Administration (FDA).

    This recall is being conducted as a result of the receipt of two previously disclosed reports outside of the U.S. of failure to activate the device due to a potential defect in a supplier component. The potential defect could make the device difficult to activate in an emergency (failure to activate or increased force needed to activate) and have significant health consequences for a patient experiencing a life-threatening allergic reaction (anaphylaxis). Both reports are related to the single lot that was previously recalled. The incidence of the defect is extremely rare and testing and analysis across the potentially impacted lots has not identified any units with a defect. However, the recall is being expanded to include additional lots as a precautionary measure out of an abundance of caution.

    The recalled product was manufactured by Meridian Medical Technologies, a Pfizer company, and distributed by Mylan Specialty between December 2015 and July 2016. The expanded voluntary recall is being initiated in the U.S. and also will extend to additional markets in Europe, Asia, North and South America.

    The recall impacts the 0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector. None of the recalled lots include the authorized generic for EpiPen Auto-Injector, which is also manufactured by Meridian Medical Technologies. 

    U.S. Impacted Lots:

    Product/Dosage

    NDC Number

    Lot Number

    Expiration Date

    EpiPen Jr 2-Pak® Auto-Injectors, 0.15 mg

    49502-501-02

    5GN767

    April 2017

    EpiPen Jr 2-Pak® Auto-Injectors, 0.15 mg

    49502-501-02

    5GN773

    April 2017

    EpiPen 2-Pak® Auto-Injectors, 0.3 mg

    49502-500-02

    5GM631

    April 2017

    EpiPen 2-Pak® Auto-Injectors, 0.3 mg

    49502-500-02

    5GM640

    May 2017

    EpiPen Jr 2-Pak® Auto-Injectors, 0.15 mg

    49502-501-02

    6GN215

    September 2017

    EpiPen 2-Pak® Auto-Injectors, 0.3 mg

    49502-500-02

    6GM082

    September 2017

    EpiPen 2-Pak® Auto-Injectors, 0.3 mg

    49502-500-02

    6GM072

    September 2017

    EpiPen 2-Pak® Auto-Injectors, 0.3 mg

    49502-500-02

    6GM081

    September 2017

    EpiPen 2-Pak® Auto-Injectors, 0.3 mg

    49502-500-02

    6GM088

    October 2017

    EpiPen 2-Pak® Auto-Injectors, 0.3 mg

    49502-500-02

    6GM199

    October 2017

    EpiPen 2-Pak® Auto-Injectors, 0.3 mg

    49502-500-02

    6GM091

    October 2017

    EpiPen 2-Pak® Auto-Injectors, 0.3 mg

    49502-500-02

    6GM198

    October 2017

    EpiPen 2-pak® Auto-Injectors, 0.3 mg

    49502-500-02

    6GM087

    October 2017

    Mylan is committed to replacing recalled devices at no cost and Mylan would like to reassure patients that there will be no additional replacement-related financial burden to them as a result of this recall. Patients, customers and distributors are being notified and should refer to Mylan.com/EpiPenRecall for updates on product return and replacement instructions. We are asking patients to keep their existing product until their replacement product can be secured.

    Patients may receive either EpiPen Auto-Injector or the authorized generic for EpiPen Auto-Injector at the pharmacy as a replacement based on availability. The authorized generic has the exact same drug formulation, has the exact same operating instructions and is therapeutically equivalent to EpiPen Auto Injector, and may be substituted for EpiPen Auto Injector.

    It is important that patients continue to carry their current EpiPen Auto-Injector until they receive a replacement device. 

    To return your product please contact Stericycle at 877-650-3494. If you have any additional questions regarding this recall, please contact Mylan Customer Relations at 800-796-9526 or customer.service@mylan.com.

    Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

    This voluntary recall is being conducted with the knowledge of FDA.

    Epinephrine is the first-line treatment for a life-threatening allergic reaction (anaphylaxis) and access to this product is critical in the event of an emergency. Delays in epinephrine administration have been associated with negative health consequences. 

    More information about the risks and benefits of EpiPen® Auto-Injector can be found at EpiPen.com.

    Please see the full Prescribing Information and Patient Information.

    Forward-Looking Statements
    This press release includes statements that constitute "forward-looking statements."  These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements, among others, that select lots of EpiPen and EpiPen Jr Auto-Injectors will be recalled; that the recall will extend to locations outside the U.S., including additional markets in Europe, Asia, and North and South America; that Mylan is committed to replacing recalled devices at no cost and that patients will experience no additional replacement-related financial burden to them as a result of this recall. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such statements.  Factors that could cause or contribute to such differences include, but are not limited to: the effect of any additional recalls of EpiPen and EpiPen Jr® Auto-Injectors; any changes in or difficulties with Mylan's or its partners' ability to develop, manufacture, and commercialize EpiPen and EpiPen Jr® Auto-Injectors or the authorized generic for EpiPen Auto-Injector; the effect of any changes in Mylan's or its partners' customer and supplier relationships and customer purchasing patterns; other changes in third-party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan or its partners; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such proceedings on Mylan's or its partners' business; any regulatory, legal, or other impediments to Mylan's or its partners' ability to bring products to market; actions and decisions of healthcare and pharmaceutical regulators, and changes in healthcare and pharmaceutical laws and regulations, in the United States and abroad; Mylan's and its partners' ability to protect intellectual property and preserve intellectual property rights; risks associated with international operations; other uncertainties and matters beyond the control of management; and the other risks detailed in Mylan's filings with the Securities and Exchange Commission. Mylan undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We market a growing portfolio of approximately 7,500 products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com. 

    SOURCE Mylan N.V.

    For further information: Nina Devlin (Media) 724.514.1968; Kris King (Investors), 724.514.1813

  • PAK Spring Events

    SPRING EVENTS
    We have a great line-up this spring, starting with a Parents Night Out-Bring Your Partner on Friday, March 31, 7:30 pm at Amélie's Café 7715 Pineville-Matthews Rd #34B, Charlotte 28226

    The parents that attended the “GET ON THE SAME PAGE AS YOUR PARTNER” meeting would like to get together again and chat some more. Veteran parents will share how they handle their differences in allergy management styles.

    Continue to scroll to see all the great educational events we have coming up which will bring us through Food Allergy Awareness Week...



RSS Feed
Top